Option Care Health (OPCH) Valuation After 2025 Results And Expanded Share Repurchase Program

Simply Wall St.03-03

Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616362927?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","is_english":true,"pubTime":"2026-03-03 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616362927","market":"us","top_or_hot":-1,"title":"Option Care Health (OPCH) Valuation After 2025 Results And Expanded Share Repurchase Program","media":"Simply Wall St.","content":"<div>\n<p>Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/option-care-health-opch-valuation-after-2025-results-and-exp\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Option Care Health (OPCH) Valuation After 2025 Results And Expanded Share Repurchase Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOption Care Health (OPCH) Valuation After 2025 Results And Expanded Share Repurchase Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 06:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/option-care-health-opch-valuation-after-2025-results-and-exp><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/option-care-health-opch-valuation-after-2025-results-and-exp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0106261612.USD","symbol_name":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/option-care-health-opch-valuation-after-2025-results-and-exp","article_id":"2616362927","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/option-care-health-opch-valuation-after-2025-results-and-exp","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616362927","pubTimestamp":1772489851,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed guidance and a larger share repurchase program.\nSee our latest analysis for Option Care Health.\nAt a share price of US$32.46, Option Care Health has seen pressure recently, with a 7 day share price return of a 10.06% decline and a 1 month share price return of a 4.53% decline. This is in contrast...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4196":"保健护理服务","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","OPCH":"Option Care Health Inc"},"translate_title":"2025年业绩和扩大股票回购计划后的Option Care Health(OPCH)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPCH":1.5},"content_text":"Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed guidance and a larger share repurchase program. See our latest analysis for Option Care Health. At a share price of US$32.46, Option Care Health has seen pressure recently, with a 7 day share price return of a 10.06% decline and a 1 month share price return of a 4.53% decline. This is in contrast to the 90 day share price return of 5.84% and the 5 year total shareholder return of 74.33%, which indicate a longer term uptrend that recent earnings news and the expanded buyback appear to have interrupted rather than reversed. If earnings volatility and reimbursement headlines have you reassessing healthcare exposure, it could be a good moment to look at our screener of 28 healthcare AI stocks as potential next ideas. With revenue and earnings guidance roughly aligned with expectations and a larger buyback now in place, the key question for you is whether Option Care Health at US$32.46 still leaves a margin of safety or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 18.5% Undervalued Option Care Health’s most followed narrative pegs fair value at $39.82, which sits well above the current $32.46 share price and frames today’s debate.  Investments in technology (AI, analytics, digital infrastructure) and clinical resource efficiency projects are supporting increased operating leverage and process automation, which is improving net margins and cash flow generation.  Read the complete narrative. Want to see what happens when rising margins, steady revenue gains, and a richer earnings multiple all pull in the same direction? The narrative sets out a tight group of assumptions around growth, profitability, and valuation that underpin that $39.82 figure. Result: Fair Value of $39.82 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still have to weigh risks like reimbursement pressure from payers and shifting therapy mix, which could squeeze margins and test that 18.5% undervalued narrative. Find out about the key risks to this Option Care Health narrative. Another View: What The P/E Is Saying That 18.5% undervalued narrative sits awkwardly next to the current P/E of 24.5x, which is higher than the US Healthcare industry at 23.7x, but lower than the 63.7x peer average and close to a 25.3x fair ratio. Is this a modest cushion or a thin one? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:OPCH P/E Ratio as at Mar 2026Next Steps If this mix of optimism and concern feels familiar, use it as a prompt to move quickly. Test the numbers yourself and see how they stack up against 2 key rewards and 1 important warning sign. Looking for more investment ideas? Before you move on, give yourself options. A few minutes with the right screeners can surface opportunities you might otherwise miss entirely.  Target potential value by scanning companies that our tools flag as 49 high quality undervalued stocks based on fundamentals and current pricing. Prioritize staying power by checking out a solid balance sheet and fundamentals stocks screener (41 results) that can help you focus on financially resilient names. Spot lesser known opportunities by running through a screener containing 24 high quality undiscovered gems that highlight quality businesses flying under most radars.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616362927","isCrawlerRequest":true}